Preview

Клиницист

Расширенный поиск

АНТИАГРЕГАНТНАЯ ТЕРАПИЯ У БОЛЬНЫХ С ВЫСОКИМ РИСКОМ РАЗВИТИЯ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ: ПРОБЛЕМА ЭФФЕКТИВНОСТИ, БЕЗОПАСНОСТИ И ПРИВЕРЖЕННОСТИ

https://doi.org/10.17650/1818-8338-2011-2-72-79

Полный текст:

Аннотация

Приведены краткие данные доказательной медицины о способности антиагрегантов, в том числе назначаемых совместно (двойная антиагрегантная терапия), улучшать прогноз жизни больных с высоким риском развития тромботических осложнений, в первую очередь пациентов, перенесших острый инфаркт миокарда. Рассмотрены проблемы выбора препарата и преодоления резистентности к нему. Представлены современные рекомендации по обеспечению безопасности терапии антиагрегантами.

Об авторах

С. Ю. Марцевич
Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития России 1-ый МГМУ им. И.М. Сеченова
Россия
Кафедра доказательной медицины


Н. П. Кутишенко
Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития России
Россия


М. Л. Гинзбург
Люберецкая районная больница № 2, Московская область
Россия


А. М. Малышева
Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития России
Россия


Ю. Н. Полянская
Государственный научно-исследовательский центр профилактической медицины Минздравсоцразвития России
Россия


Список литературы

1. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;332:349–60.

2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002;324:71–86.

3. Yusuf S., Zhao F., Mehta S.R., et al.; the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

4. Chen Z.M., Jiang L.X., Chen Y.P., et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial

5. infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–21.

6. Montalescot G., Wiviott S., Braunwald E., et al.; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double blind, randomised controlled trial. Lancet

7. ;373:723–31.

8. Cannon C., Harrington R., James S., et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised doubleblind study. Lancet 2010;375:283–93.

9. Stone G.W. Ticagrelor in ASC: redefining a new standard of care? Lancet 2010;375:263–5.

10. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598–660.

11. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909–45.

12. Abraham N., Hlatky M., Antman E., et al. ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal

13. risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122(24):2619–33.

14. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

15. Moukarbel G., Signorovitch J., Pfeffer M., et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009;30:2226–32.

16. Bhatt D.L., Scheiman J., Abraham N.S., et al.; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAIDS use: a report of the American College of CArdiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894–909.

17. Kitchingman G.K., Prichard P.J., Daneshmend T.K., et al. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine. Br J Clin Pharmacol1989;28:581–5.

18. Krasopoulos G., Brister S., Beattie W., Buchanan M.R. Aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336(7637):195–8.

19. Gasparyan A., Watson T., Lip G. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008;51:1829–43.

20. Trenk D., Hochholzer W., Fromm M.F., et al. Cytochrome p450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective

21. percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll

22. Cardiol 2008;51:1925–34.

23. Mega J.L., Close S.L., Wiviott S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRINON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376(9749):1312–9.

24. Holmes D.R. Jr., Dehmer G.J., Kaul S., et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on

25. clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56(4):321–41.

26. Pare G., Mehta S., Yusuf S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704–14.

27. Mehta S., Tanguay J.F., Eikelboom J.W., et al. Double-dose versus standard-dose clopidogrel and high-dose versus lowdose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376(9748):1233–43.

28. Mega J.L., Close S.L., Wiviott S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376(9749):1312–9.

29. Wallentin L., James S., Storey R.F., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lance 2010;376(9749):1320–8.

30. Bhatt D.L., Cryer B.L., Contant C.F., et al.; COGENT Investigators. Clopidogrel with or without omeprazolein coronary artery disease. N Engl J Med 2010;363:1909–17.

31. Simon T., Steg P.G., Gilard M., et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-STElevation

32. Myocardial Infarction (FAST-MI) Registry. Circulation 2011;123(5):474–82.

33. Ferriero J.L., Ueno N., Capodanno D., et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study.

34. Circ Cardiovasc Interv 2010;3:436–41.

35. Sung J., Lau J., Ching J., et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152(1):1–9.


Для цитирования:


Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., Малышева А.М., Полянская Ю.Н. АНТИАГРЕГАНТНАЯ ТЕРАПИЯ У БОЛЬНЫХ С ВЫСОКИМ РИСКОМ РАЗВИТИЯ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ: ПРОБЛЕМА ЭФФЕКТИВНОСТИ, БЕЗОПАСНОСТИ И ПРИВЕРЖЕННОСТИ. Клиницист. 2011;5(2):72-79. https://doi.org/10.17650/1818-8338-2011-2-72-79

For citation:


Martsevich S.Y., Kutishenko N.P., Ginzburg M.L., Malysheva A.M., Polyanskaya Y.N. ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: THE PROBLEM OF EFFICIENCY, SAFETY AND COMPLIANCE. The Clinician. 2011;5(2):72-79. (In Russ.) https://doi.org/10.17650/1818-8338-2011-2-72-79

Просмотров: 399


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8338 (Print)
ISSN 2412-8775 (Online)